wr 1065 has been researched along with Disease Models, Animal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bornhorst, J; Brinkmann, V; Crone, B; Fritz, G; Hennecke, T; Honnen, S; Karst, U; Kurzke, J; Weides, L; Wellenberg, A | 1 |
| Chan, LP; Chang, LC; Chen, CH; Kuo, ML; Liao, WC; Lin, J; Wang, JL | 1 |
| Haddadi, R; Jorjani, M; Khalifeh, S; Kheradmand, A; Nayebi, AM | 1 |
| DeRemer, SJ; Dou, C; Ensminger, WD; Levi, M; Smith, DE | 1 |
4 other study(ies) available for wr 1065 and Disease Models, Animal
| Article | Year |
|---|---|
Use of C. elegans as a 3R-compliant in vivo model for the chemoprevention of cisplatin-induced neurotoxicity.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Caenorhabditis elegans; Chemoprevention; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Mercaptoethylamines; Neurotoxicity Syndromes; Oxidative Stress; Platinum Compounds | 2021 |
CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice.
Topics: Acute Radiation Syndrome; Amifostine; Animals; Disease Models, Animal; Dose-Response Relationship, Radiation; Male; Mercaptoethylamines; Mice; Mice, Inbred C57BL; Micelles; Polyethylene Glycols; Radiation-Protective Agents; Whole-Body Irradiation | 2015 |
Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
Topics: Animals; Disease Models, Animal; Glutathione; Inflammation; Interleukin-1beta; Lipid Peroxidation; Male; Malondialdehyde; Mercaptoethylamines; Motor Activity; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2016 |
Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Disease Models, Animal; Drug Delivery Systems; Drug Screening Assays, Antitumor; Femoral Vein; Infusions, Intravenous; Liver Neoplasms, Experimental; Male; Mercaptoethylamines; Neoplasm Transplantation; Portal Vein; Prodrugs; Rats; Rats, Sprague-Dawley | 2004 |